Kyle M Devins, Zehra Ordulu, Rachelle P Mendoza, Sabrina Croce, Rishikesh Haridas, Pankhuri Wanjari, Andre Pinto, Esther Oliva, Jennifer A Bennett
Uterine inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms of uncertain malignant potential. Aside from the recently described risk stratification score, which has not been validated by other studies, and rare reports of aberrant p16 expression in malignant tumors, there are no criteria to reliably predict behavior. Herein, we evaluated the clinicopathologic features and p16 expression patterns in 30 IMTs, with genomic profiling performed in a subset (13 malignant, 3 benign). Fifteen patients had malignant IMTs, defined by extrauterine disease at diagnosis (n=5) or recurrence (n=10; median: 24 mo)...
April 17, 2024: American Journal of Surgical Pathology